List of Excipients in Branded Drug BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis US LLC	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	benazepril hydrochloride and hydrochlorothiazide	0574-0227	CELLULOSE, MICROCRYSTALLINE
Padagis US LLC	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	benazepril hydrochloride and hydrochlorothiazide	0574-0227	CROSPOVIDONE
Padagis US LLC	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	benazepril hydrochloride and hydrochlorothiazide	0574-0227	FERRIC OXIDE RED

Generic Drugs Containing BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Sandoz Inc	benazepril hydrochloride and hydrochlorothiazide	0185-0236	CROSPOVIDONE
Sandoz Inc	benazepril hydrochloride and hydrochlorothiazide	0185-0236	HYDROGENATED CASTOR OIL
Sandoz Inc	benazepril hydrochloride and hydrochlorothiazide	0185-0236	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
2	CELLULOSE, MICROCRYSTALLINE
2	COLLOIDAL SILICON DIOXIDE

# Benazepril Hydrochloride and Hydrochlorothiazide: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 8, 2026

Benazepril hydrochloride/hydrochlorothiazide is an established fixed-dose antihypertensive combination with limited remaining exclusivity value and a primarily generic commercial opportunity. The formulation challenge is not new chemical entity protection. It is reliable low-dose content uniformity, moisture control, tablet robustness, dissolution performance, and cost-efficient manufacturing across multiple strengths.

The combination pairs benazepril, an angiotensin-converting enzyme inhibitor, with hydrochlorothiazide, a thiazide diuretic. The reference product, Lotensin HCT, was approved by the U.S. Food and Drug Administration in the 1990s. Current opportunity is concentrated in generic supply, contract manufacturing, private-label products, differentiated dosage forms, and improved adherence packaging rather than conventional patent exclusivity.

What is the FDA status of benazepril hydrochloride and hydrochlorothiazide?

Benazepril hydrochloride/hydrochlorothiazide is an FDA-approved fixed-dose combination for hypertension. The product is administered orally as tablets in multiple strengths, including combinations based on benazepril hydrochloride 5 mg, 10 mg, or 20 mg with hydrochlorothiazide 6.25 mg, 12.5 mg, or 25 mg, depending on the marketed product.

Attribute	Regulatory position
Active ingredients	Benazepril hydrochloride and hydrochlorothiazide
Dosage form	Immediate-release oral tablet
Therapeutic category	Antihypertensive
FDA pathway	NDA for the reference product; ANDA pathway for generics
Reference brand	Lotensin HCT
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
Main regulatory standard	Pharmaceutical equivalence and bioequivalence
Primary commercial channel	Generic prescription market

FDA labeling identifies the product as a combination antihypertensive and includes warnings relating to fetal toxicity, hypotension, renal impairment, electrolyte abnormalities, and hypersensitivity reactions associated with ACE inhibitors and thiazide diuretics (U.S. Food and Drug Administration [FDA], n.d.-a).

Because the product is a small-molecule tablet, a follow-on manufacturer generally files an ANDA rather than a 351(k) biosimilar application. The key regulatory work is formulation development, analytical method validation, in vitro dissolution, stability, manufacturing controls, and bioequivalence.

What excipients are used in benazepril hydrochloride/hydrochlorothiazide tablets?

Public labeling for marketed products identifies common tablet excipients including lactose monohydrate, microcrystalline cellulose, crospovidone, hypromellose, magnesium stearate, colloidal silicon dioxide, talc, and titanium dioxide, although the precise composition varies by manufacturer and strength (FDA, n.d.-a; National Library of Medicine, n.d.).

A representative excipient architecture is:

Formulation function	Common excipient candidates	Commercial purpose
Diluent	Lactose monohydrate, microcrystalline cellulose	Provides tablet mass and improves compressibility
Disintegrant	Crospovidone	Promotes rapid tablet breakup
Binder or film former	Hypromellose	Supports granulation or film coating
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate	Reduces ejection force and sticking
Anti-adherent or coating aid	Talc	Supports processing and coating performance
Opacifier or colorant	Titanium dioxide or approved alternatives	Enables product identification and appearance control

The selected excipient system must accommodate two active ingredients with different dose levels and potentially different particle-size, flow, and compression characteristics. Hydrochlorothiazide is present at relatively low milligram levels in some strengths, creating a content-uniformity challenge. Benazepril hydrochloride is also used at low dose relative to total tablet weight.

How should the formulation manage low-dose content uniformity?

Uniform distribution of hydrochlorothiazide is a central development issue. A manufacturer can use direct compression if both active ingredients have suitable flow and blend uniformity. Wet granulation or dry granulation may provide better segregation control when particle-size or density differences cause blend instability.

The most practical development sequence is:

1. Characterize active-ingredient particle size, morphology, density, moisture sensitivity, and electrostatic behavior.
2. Select a premix or ordered-mixture approach for the lower-dose component.
3. Establish blend-time and sampling-location controls.
4. Evaluate segregation during hopper discharge and tablet compression.
5. Confirm assay and uniformity across the beginning, middle, and end of the compression run.
6. Link blend uniformity to finished-tablet content uniformity and dissolution.

A formulation that passes laboratory blending but segregates during scale-up presents a material commercial risk. This is particularly relevant when manufacturing multiple strengths on shared equipment.

What excipient strategy is most commercially attractive?

The strongest general strategy is a conventional immediate-release tablet using widely accepted excipients, a low number of processing steps, and a coating system that supports differentiation without creating regulatory complexity.

Strategy 1: Low-cost direct compression

Direct compression can minimize equipment, cycle time, solvent exposure, and manufacturing cost. Microcrystalline cellulose, lactose, crospovidone, colloidal silicon dioxide, and magnesium stearate are common choices.

This approach is attractive when:

• The active ingredients have acceptable flow.
• Segregation is controlled.
• Tablet hardness and friability remain within specification.
• Dissolution is robust across commercial-scale batches.
• The manufacturer can maintain content uniformity at the lowest strength.

The main risk is poor blend uniformity caused by differences in particle size or density.

Strategy 2: Dry granulation

Roller compaction can improve flow and reduce segregation without adding water. It is useful where the active ingredients or formulation are moisture-sensitive, or where direct compression produces unacceptable weight variation.

The tradeoff is higher process complexity and the need to control ribbon density, granule-size distribution, fines, and tabletability.

Strategy 3: Wet granulation

Wet granulation can improve content uniformity and compressibility, but it adds drying, residual-moisture, and process-control requirements. It is less attractive if benazepril hydrochloride or the selected excipient system shows sensitivity to water, heat, or extended processing time.

Strategy 4: Excipients for sensitive-patient positioning

A lactose-free, low-allergen, or simplified-excipient version could support pharmacy and institutional purchasing requirements. However, this would be a commercial differentiation strategy rather than a substitute for clinical evidence. Changing from lactose to anhydrous dibasic calcium phosphate, mannitol, or additional microcrystalline cellulose can alter density, hardness, disintegration, dissolution, and manufacturability.

A lactose-free product may have value in selected channels, but the opportunity is narrower than the general generic market. The product would need a clear procurement or patient-use rationale.

What formulation patents protect benazepril hydrochloride/hydrochlorothiazide?

The principal commercial protection for the fixed-dose combination arose from the original product and related regulatory exclusivity. The basic combination is no longer a strong exclusivity platform.

Protection category	Current commercial relevance
Compound patents	Expired or commercially exhausted for the marketed actives
Fixed-dose combination patents	No apparent durable barrier to ordinary generic entry
Immediate-release tablet patents	Limited relevance unless a specific later formulation is listed
Method-of-use patents	Limited value for standard hypertension treatment
Manufacturing patents	Potentially useful as process know-how, but rarely sufficient to block routine generic entry
Excipient patents	Generally weak unless tied to a demonstrably novel delivery or stability result
Regulatory exclusivity	Historical value; not a current barrier to mature generic supply

The FDA Orange Book is the relevant source for listed patents and exclusivity associated with approved drug products. Any patent analysis should distinguish patents listed for the reference product from patents owned by third parties but not listed in the Orange Book (FDA, n.d.-b).

For this combination, the commercially relevant IP opportunity is more likely to involve a genuinely differentiated product, such as modified release, an orally disintegrating tablet, a multiparticulate system, or a validated stability improvement, rather than a conventional excipient substitution.

When does benazepril hydrochloride/hydrochlorothiazide lose exclusivity?

The product has already passed the period in which basic brand exclusivity could support a premium. The historical reference-product exclusivity period has expired, and generic versions have been available or developed through the ANDA pathway.

The relevant present-day question is not when the original product loses exclusivity. It is whether a new formulation can obtain independent protection. Potential protection could arise from:

• A new dosage form.
• A new release profile.
• A novel tablet architecture.
• A stability-enhancing excipient system.
• A medically meaningful method of use.
• A pediatric formulation.
• A fixed-dose combination with a new strength or administration schedule, where supported by FDA requirements.

A new patent must provide more than a routine substitution of lactose, microcrystalline cellulose, or a conventional superdisintegrant. Patentability would generally depend on novelty, non-obviousness, adequate disclosure, and a defensible technical effect under U.S. patent law.

How many patents cover the product, and what is the Orange Book status?

The conventional immediate-release combination does not present a meaningful active-patent barrier comparable to a recently approved branded medicine. The Orange Book should be checked by product name, NDA number, dosage form, and strength before filing or acquisition decisions because listings can change and patent status can differ by product presentation.

Question	Assessment
Are active-ingredient patents a barrier?	No meaningful barrier for ordinary generic development
Are formulation patents a major barrier?	Not for the conventional immediate-release product based on the mature market position
Is an Orange Book patent certification required for an ANDA?	Yes, where applicable to listed patents
Is Paragraph IV litigation likely for the original product?	Low strategic relevance for an already mature combination
Is patent clearance still necessary?	Yes, for any listed patent, third-party formulation claim, or process claim

FDA’s Orange Book records and current product labeling remain the controlling sources for regulatory and listing determinations (FDA, n.d.-b).

Are Paragraph IV challenges and generic entry risks material?

The combination is exposed to ordinary generic competition rather than a new wave of Paragraph IV value creation. For a new ANDA, the applicant must make the applicable patent certifications. If a listed patent remains relevant, a Paragraph IV certification could create litigation risk and potentially a 30-month stay under the Hatch-Waxman framework if the statutory conditions are satisfied.

Commercial risks include:

• Multiple approved ANDAs competing on price.
• Low reimbursement ceilings.
• Pharmacy substitution.
• Limited differentiation between manufacturers.
• Active-ingredient supply interruptions.
• Manufacturing-site qualification delays.
• Product discontinuation when net prices fall below sustainable margins.

A generic entrant may still obtain a first-to-file advantage in a specific circumstance, but that value depends on a qualifying Paragraph IV filing and the applicable Orange Book record. It should not be assumed for this mature combination.

What manufacturing and IP barriers affect the product?

The most significant barriers are operational rather than patent-based.

Manufacturing barriers

Manufacturers must control:

• Blend segregation at low hydrochlorothiazide loadings.
• Moisture and temperature exposure.
• Tablet weight variation.
• Lubrication time and magnesium stearate distribution.
• Dissolution across all strengths.
• Coating uniformity and product identification.
• Stability under long-term and accelerated conditions.
• Scale-up from laboratory blend to commercial batch.

A manufacturer with validated high-containment or multi-product solid-dose capacity can compete effectively if it has reliable active-ingredient sourcing and low deviation rates.

Manufacturing know-how as an IP asset

Process know-how can have commercial value even when it does not create a strong blocking patent. Examples include:

• A premix process that improves hydrochlorothiazide distribution.
• A low-shear blending sequence that reduces segregation.
• A moisture-controlled granulation process.
• A coating formulation that improves stability without delaying dissolution.
• A common platform that supports several benazepril/hydrochlorothiazide strengths.

Trade-secret value is strongest when the process produces measurable yield, quality, or cost advantages and is difficult to reverse engineer from the finished tablet.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have several potential entry points, but the largest volume opportunity is likely a conventional tablet platform rather than a premium excipient product.

High-probability opportunities

Opportunity	Demand rationale	Commercial attractiveness
Microcrystalline cellulose/lactose platform	Supports low-cost immediate-release tablets	High volume, low differentiation
Crospovidone or alternative disintegrant	Helps achieve rapid tablet breakup	Moderate
Low-moisture excipient system	Supports stability and process control	Moderate to high if validated
Direct-compression grade excipients	Reduces manufacturing steps	High for generic manufacturers
Lactose-free formulation platform	Addresses selected patient and procurement needs	Niche
Film-coating system	Supports identification and appearance	Moderate
Excipient premix	Improves low-dose blend uniformity	Potentially strong if performance is demonstrated
Continuous-manufacturing formulation	Reduces process variation and labor	Strategic, but customer adoption is slower

The strongest value proposition is a validated excipient system that solves a specific manufacturing problem. Generic claims such as “improves compression” are less persuasive than data showing lower content-uniformity variability, shorter processing time, improved dissolution robustness, or reduced tablet defects.

How does benazepril/hydrochlorothiazide compare with other antihypertensive combinations?

The combination is commercially less attractive than newer, higher-volume fixed-dose combinations involving amlodipine, losartan, valsartan, or other widely prescribed agents. Its advantages are established clinical use, familiar manufacturing technology, and relatively simple regulatory positioning.

Product class	Competitive position
Benazepril/hydrochlorothiazide	Mature ACE inhibitor/thiazide combination
Lisinopril/hydrochlorothiazide	Broader generic presence and strong historical volume
Losartan/hydrochlorothiazide	Large ARB/thiazide market and strong substitution pressure
Valsartan/hydrochlorothiazide	Established ARB combination with supply-chain sensitivity
Amlodipine/benazepril	Competes for patients needing calcium-channel-blocker plus ACE-inhibitor therapy
Triple antihypertensive products	May offer stronger adherence proposition but greater formulation complexity

The main commercial disadvantage is generic price erosion. A new entrant needs manufacturing efficiency, dependable supply, or a channel-specific differentiation strategy.

What revenue exposure and launch scenarios exist?

The product is unlikely to support meaningful branded revenue without a differentiated formulation or strong distribution position. Revenue exposure depends on market share, net price, supply reliability, and the number of competing ANDAs.

Generic launch scenarios

Scenario	Product strategy	Expected commercial profile
Commodity launch	Conventional immediate-release tablets	Fastest development; highest price pressure
Supply-reliability launch	Same dosage form with redundant manufacturing and inventory	Attractive to wholesalers and health systems
Formulation-differentiation launch	Lactose-free, smaller tablet, or improved coating	Modest premium potential
Adherence-oriented launch	Unit-dose packaging or synchronized strengths	Channel-specific value
Lifecycle product	New release profile or alternative dosage form	Higher development cost and regulatory risk
Platform launch	Several strengths and related ACE inhibitor combinations	Better portfolio economics

Unit-dose packaging, 90-day supply, and hospital or managed-care contracting may create more practical value than a marginal excipient change. A portfolio covering the common strengths can improve manufacturing utilization and reduce customer switching costs.

What litigation and settlement agreements affect the product?

There is no apparent current litigation issue that defines the commercial position of the conventional combination. Historical patent litigation and settlement agreements, if any, must be reviewed through the FDA Orange Book, court dockets, and FTC pharmaceutical settlement materials before relying on a specific launch date or market-share assumption.

For a current generic program, the more relevant legal questions are:

• Whether the Orange Book contains an active listed patent.
• Whether a third party asserts formulation or process claims.
• Whether the proposed formulation creates an ANDA certification issue.
• Whether a distributor or manufacturer has contractual exclusivity.
• Whether a supply agreement restricts private-label sales.
• Whether a settlement contains launch restrictions or licenses.

Patent clearance should cover U.S. and foreign family members, continuation applications, manufacturing claims, and product-by-process claims. A conventional excipient choice normally does not eliminate the need for freedom-to-operate review.

What geographic coverage exists?

The product has the broadest commercial relevance in markets that recognize fixed-dose generic antihypertensive tablets and use ACE inhibitor/thiazide therapy. Regulatory requirements differ by region.

Region	Key consideration
United States	ANDA, Orange Book, bioequivalence, cGMP
European Union	Marketing authorization, pharmaceutical equivalence, bioequivalence, national substitution rules
Canada	Generic drug submission and provincial reimbursement
Emerging markets	Local registration, price controls, local manufacturing or tender requirements
Hospital markets	Supply reliability, dossier completeness, and procurement pricing

Excipient acceptability must be assessed against the relevant jurisdiction’s approved excipient standards and product-specific labeling. A formulation optimized for U.S. generic filing may require changes for European or emerging-market registration because of colorants, lactose labeling, coating components, or local pharmacopeial expectations.

How strong is the patent estate for benazepril/hydrochlorothiazide?

The patent estate is weak as a basis for protecting a conventional tablet. Its commercial strength is better described as operational and regulatory.

Estate component	Relative strength
Core active ingredients	Low
Original fixed-dose combination	Low
Conventional excipient formulation	Low
Novel delivery system	Potentially moderate to strong
Manufacturing process	Moderate if technically specific and difficult to design around
Trade secrets	Moderate where process performance is superior
Regulatory dossier and manufacturing history	Valuable commercially, but not exclusionary

A company considering licensing should prioritize supply agreements, manufacturing capacity, distribution access, and differentiated formulation data over acquisition of legacy composition patents.

Key Takeaways

• Benazepril hydrochloride/hydrochlorothiazide is a mature small-molecule fixed-dose tablet with no biosimilar pathway.
• The original brand exclusivity position has expired, and generic competition is the central market fact.
• Common excipients include lactose monohydrate, microcrystalline cellulose, crospovidone, hypromellose, colloidal silicon dioxide, magnesium stearate, talc, and coating materials.
• Low-dose hydrochlorothiazide content uniformity, segregation, moisture control, and dissolution are the main formulation risks.
• Direct compression offers the clearest low-cost strategy, while dry granulation may improve robustness where flow or segregation is problematic.
• Conventional excipient substitution is unlikely to create strong patent protection.
• Commercial opportunity is strongest in reliable supply, private-label manufacturing, multi-strength portfolios, lactose-free positioning, and validated excipient premixes.
• Orange Book and patent clearance remain necessary for any new ANDA, even though the mature combination does not present a major apparent exclusivity barrier.
• A new formulation would need a measurable technical advantage to justify development cost and potential patent investment.

FAQs

Is benazepril hydrochloride/hydrochlorothiazide still commercially attractive?

Yes, but mainly as a low-cost generic, contract-manufacturing, or supply-reliability opportunity. It is unlikely to support a premium brand without a differentiated dosage form or channel strategy.

Can lactose be removed from the formulation?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another suitable diluent. The change requires new development work for compression, disintegration, dissolution, stability, and bioequivalence.

Is hydrochlorothiazide the main content-uniformity risk?

It is one of the principal risks because it is used at a low dose in some strengths. Particle-size matching, premixing, granulation, and segregation testing are important controls.

Would an orally disintegrating tablet have patent potential?

Potentially. Patent value would depend on a non-obvious formulation, reproducible performance, acceptable taste, stability, and a credible technical advantage over known orally disintegrating systems.

Does the product require a biosimilar application?

No. Benazepril hydrochloride and hydrochlorothiazide are small molecules. A generic applicant generally uses the ANDA pathway and must address pharmaceutical equivalence, bioequivalence, quality, and applicable patent certifications.

References

1. National Library of Medicine. (n.d.). DailyMed: Benazepril hydrochloride and hydrochlorothiazide tablet labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-a). Lotensin HCT and benazepril hydrochloride/hydrochlorothiazide prescribing information. FDA. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.-c). Inactive ingredient database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.